Advanced glycation end products: A risk factor for human health;Les produits de glycation avancée: Un risque pour la santé humaine

Annales Pharmaceutiques Francaises

Volumn 72, Issue 6, 2014, Pages 400-408

  Wautier, M P ^a   Tessier, F J ^b   Wautier, J L ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSTITUT POLYTECHNIQUE LASALLE BEAUVAIS   (France)

Author keywords

Advanced glycation end products; Cytokines; Diabetes; Endothelium; Maillard; Vascular permeability

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CELL ADHESION MOLECULE; CYTOKINE; FREE RADICAL; GROWTH FACTOR; REACTIVE OXYGEN METABOLITE; VASCULOTROPIN; ADVANCED GLYCATION END PRODUCT RECEPTOR; AGER PROTEIN, HUMAN;

BLOOD VESSEL INJURY; BLOOD VESSEL PERMEABILITY; DIABETIC ANGIOPATHY; DIABETIC RETINOPATHY; ENDOTHELIUM CELL; GLYCATION; HUMAN; INTRACELLULAR SIGNALING; LEUKOCYTE MIGRATION; MACROPHAGE; MONOCYTE; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; RISK FACTOR; GENETICS; METABOLISM; PHYSIOLOGY;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; RISK FACTORS;

EID: 84922707236     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2014.05.002     Document Type: Review

References (45)

1. Maillard L.C. Action des acides aminés sur les sucres: formation des mélanoïdines par voie méthodique. C R Acad Sci 1912, 154:66-68.
2. Wautier J.L. Le sens de la médecine ou la révolution culturelle dans le système de santé 2013, L'Harmattan, Paris.
3. Ahmed M.U., Thorpe S.R., Baynes J.W. Identification of N epsilon carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 1986, 261:4889-4894.
4. Büser W., Erbersdobler H.F. Carboxymethyllysine, a new compound of heat damage in milk products. Milchwiss 1986, 41:780-785.
5. Koschinsky T., He C.J., Mitsuhashi T., Bucala R., Liu C., Buenting C., et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A 1997, 94:6474-6479.
6. Zheng F., He C., Cai W., Hattori M., Steffes M., Vlassara H. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab Res Rev 2002, 18:224-237.
7. Lin R.Y., Choudhury R.P., Cai W., Lu M., Fallon J.T., Fisher E.A., et al. Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 2003, 168:213-220.
8. Hofmann S.M., Dong H.J., Li Z., Cai W., Altomonte J., Thung S.N., et al. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes 2002, 51:2082-2089.
9. Birlouez-Aragon I., Saavedra G., Tessier F.J., Galinier A., Ait-Ameur L., Lacoste F., et al. A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases. Am J Clin Nutr 2010, 91:1-7.
10. Tessier F.J., Birlouez-Aragon I. Health effects of dietary Maillard reaction products: the results of ICARE and other studies. Amino Acids 2012, 42:1119-1131.
11. Henle T. Dietary advanced glycation end products - a risk to human health? A call for an interdisciplinary debate. Mol Nutr Food Res 2007, 51:1075-1078.
12. Krug E., Prellwitz W., Schaffner E. Thermische Eiweissveranderungen und biologische Wertigkeit. Naturwissenschaften 1959, 46:534-535.
13. Tessier F.J., Niquet C. État des connaissances sur la biodisponibilité et la toxicité des produits de Maillard issus de l'alimentation. J Soc Biol 2007, 201:199-207.
14. International Agency of Research on Cancer (IARC) Agents classified by the IARC monographs 2014, vol. 1-109. IARC, Lyon, France, Available from: http://monographs.iarc.fr/ENG/Classification/index.php [last update: 18February 2014].
15. Mottram D.S., Wedzicha B.L., Dodson A.T. Acrylamide is formed in the Maillard reaction. Nature 2002, 419(6906):448-449.
16. Tareke E., Rydberg P., Karlsson P., Eriksson S., Törnqvist M. Acrylamide: a cooking carcinogen?. Chem Res Toxicol 2000, 13:517-522.
17. Sirot V., Hommet F., Tard A., Leblanc J.C. Dietary acrylamide exposure of the French population: results of the second French Total Diet Study. Food Chem Toxicol 2012, 50:889-894.
18. ε-carboxymethyllysine in coffee substitutes and instant coffees. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2014, 31(4):593-604.
19. Lipworth L., Sonderman J.S., Tarone R.E., McLaughlin J.K. Review of epidemiologic studies of dietary acrylamide intake and the risk of cancer. Eur J Cancer Prev 2012, 21:375-386.
20. ANSES Étude de l'alimentation totale française 2 (EAT 2). Résidus de pesticides, additifs, acrylamide, hydrocarbures aromatiques polycycliques 2011, ANSES, Maisons-Alfort, France, [Saisine no 2006-SA-0361]. Tome 2.
21. Medeiros Vinci R., Mestdagh F., De Meulenaer B. Acrylamide formation in fried potato products - Present and future, a critical review on mitigation strategies. Food Chem 2012, 133:1138-1154.
22. Loaëc G., Niquet-Léridon C., Henry N., Jacolot P., Volpoet G., Goudemand E., et al. Effects of variety, agronomic factors, and drying on the amount of free asparagine and crude protein in chicory. Correlation with the acrylamide formation during roasting. Food Res Int 2014, [Available on line 13March 2014]. 10.1016/j.foodres.2014.03.010.
23. FoodDrinkEurope Acrylamide Toolbox 2013 2014, FoodDrinkEurope, Brussels, Available from:. http://www.fooddrinkeurope.eu/publications/category/toolkits/.
24. Wautier J.L., Schmidt A.M. Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 2004, 95:233-238.
25. Hudson B.I., Carter A.M., Harja E., Kalea A.Z., Arriero M., Yang H., et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J 2008, 22:1572-1580.
26. Berrou J., Tostivint I., Verrecchia F., Berthier C., Boulanger E., Mauviel A., et al. Advanced glycation end products regulate extracellular matrix protein and protease expression by human glomerular mesangial cells. Int J Mol Med 2009, 23:513-520.
27. Lue L.F., Walker D.G., Jacobson S., Sabbagh M. Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases. Future Neurol 2009, 4:167-177.
28. Yan S.F., Ramasamy R., Naka Y., Schmidt A.M. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003, 93:1159-1169.
29. Li J.H., Wang W., Huang X.R., Oldfield M., Schmidt A.M., Cooper M.E., et al. Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2MAP kinase signaling pathway. Am J Pathol 2004, 164:1389-1397.
30. Ishihara K., Tsutsumi K., Kawane S., Nakajima M., Kasaoka T. The receptor for advanced glycation end products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Lett 2003, 550:107-113.
31. Wautier J.L., Wautier M.P., Schmidt A.M., Anderson G.M., Hori O., Zoukourian C., et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci U S A 1994, 91:7742-7746.
32. Wautier J.L., Zoukourian C., Chappey O., Wautier M.P., Guillausseau P.J., Cao R., et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 1996, 97:238-243.
33. Kislinger T., Tanji N., Wendt T., Qu W., Lu Y., Ferran L.J., et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2001, 21:905-910.
34. Grossin N., Wautier J.L. Protein glycation and endothelium dysfunction. J Soc Biol 2007, 201:175-184.
35. Wautier M.P., Khodabandehlou T., Le Devehat C., Wautier J.L. Modulation of RAGE expression influences the adhesion of red blood cells from diabetic patients. Clin Hemorheol Microcirc 2006, 35:379-386.
36. Grossin N., Wautier M.P., Wautier J.L. Red blood cell adhesion in diabetes mellitus is mediated by advanced glycation end product receptor and is modulated by nitric oxide. Biorheology 2009, 46:63-72.
37. Lo C.Y., Li S., Tan D., Pan M.H., Sang S., Ho C.T. Trapping reactions of reactive carbonyl species with tea polyphenols in simulated physiological conditions. Mol Nutr Food Res 2006, 50:1118-1128.
38. Huang S.M., Hsu C.L., Chuang H.C., Shih P.H., Wu C.H., Yen G.C. Inhibitory effect of vanillic acid on methylglyoxal-mediated glycation in apoptotic Neuro-2A cells. Neurotoxicology 2008, 29:1016-1022.
39. Ahmad M.S., Ahmed N. Antiglycation properties of aged garlic extract: possible role in prevention of diabetic complications. J Nutr 2006, 136:796S-799S.
40. Hammes H.P., Du X., Edelstein D., Taguchi T., Matsumura T., Ju Q., et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003, 9:294-299.
41. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
42. Chen J.L., Francis J. Pyridoxamine, advanced glycation inhibition and diabetic nephropathy. J Am Soc Nephrol 2012, 23(1):6-8.
43. Forbes J.M., Thorpe S.R., Thallas-Bonke V., Pete J., Thomas M.C., Deemer E.R., et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1inhibition in diabetic nephropathy. J Am Soc Nephrol 2005, 16:2363-2372.
44. Wautier M.P., Chappey O., Corda S., Stern D.M., Schmidt A.M., Wautier J.L. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001, 280:E685-E694.
45. Yamagishi S., Matsui T., Nakamura K., Inoue H., Takeuchi M., Ueda S., et al. Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. Microvasc Res 2008, 75:130-134.